Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Brain implant technology startup Science Corp. raises $400M to bring its medical devices to market

Brain-computer interface company Science Corp. today revealed it has raised $400 million in a late-stage round of funding that brings its valuation to $3.5 billion. The Series D round, announced in a blog post today, was led by high-profile venture capital firm Khosla Ventures. It was joined by the Ackman Oxman Institute, Tenet Healthcare, 885 […] The post Brain implant technology startup Science…

Brain implant technology startup Science Corp. raises $400M to bring its medical devices to market

Brain-computer interface startup Science Corp. has secured $400 million in a late-stage funding round, bringing its valuation to $3.5 billion. The Series D round was led by Khosla Ventures, with participation from notable investors such as the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech. The funding will enable the company to bring its flagship product, PRIMA, to the U.S. healthcare market after already gaining traction in Europe.

PRIMA is a specialized chip implanted in the eyes of patients suffering from age-related macular degeneration (AMD), one of the leading causes of vision loss in older adults. The chip is paired with glasses that help restore partial vision to AMD sufferers and has already been approved for use in several European countries, including Germany.

Science plans to offer PRIMA to patients who can afford it at a special unit at Moorfields Private Eye Hospital in London, though the exact cost has not been disclosed. The device is currently being reviewed by the FDA for potential approval in the U.S., with initial availability expected early next year.

Science Corp. is also developing the Biohybrid implant, a direct brain implant built from cultured neurons combined with silicon chips and integrated with the brain's circuits. The company has identified Parkinson's disease as its first target for this technology but has not disclosed any other planned treatments. So far, Biohybrid has only been tested on animals, with human clinical trials planned within the next 16 months.

Written by urgent.news from SiliconANGLE's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at siliconangle.com →

More in Finance & Markets

More from Wednesday 18 November →